{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:43:03Z","timestamp":1791398583186,"version":"4.3.3"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41401-025-01663-y","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T13:22:30Z","timestamp":1758288150000},"page":"493-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TNFSF15 alleviates myeloid-derived suppressor cell-mediated cancer immunosuppression in mice"],"prefix":"10.1038","volume":"47","author":[{"given":"Yi-pan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-yu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-ju","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-song","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"1663_CR1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"1663_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120:16\u201325.","journal-title":"Br J Cancer"},{"key":"1663_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6:362.","journal-title":"Signal Transduct Target Ther"},{"key":"1663_CR4","doi-asserted-by":"publisher","first-page":"3849","DOI":"10.1158\/1078-0432.CCR-15-1912","volume":"22","author":"Y Mao","year":"2016","unstructured":"Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin Cancer Res. 2016;22:3849\u201359.","journal-title":"Clin Cancer Res"},{"key":"1663_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1158\/0008-5472.CAN-13-1545","volume":"74","author":"D Alizadeh","year":"2014","unstructured":"Alizadeh D, Trad M, Hanke NT, Larmonier CB, Janikashvili N, Bonnotte B, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 2014;74:104\u201318.","journal-title":"Cancer Res"},{"key":"1663_CR6","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-09-3272","volume":"16","author":"S Nagaraj","year":"2010","unstructured":"Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010;16:1812\u201323.","journal-title":"Clin Cancer Res"},{"key":"1663_CR7","first-page":"4441","volume":"63","author":"S Kusmartsev","year":"2003","unstructured":"Kusmartsev S, Cheng F, Yu B, Nefedova Y, Sotomayor E, Lush R, et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 2003;63:4441\u20139.","journal-title":"Cancer Res"},{"key":"1663_CR8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","volume":"13","author":"JE Talmadge","year":"2013","unstructured":"Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013;13:739\u201352.","journal-title":"Nat Rev Cancer"},{"key":"1663_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u201368.","journal-title":"Nat Rev Immunol"},{"key":"1663_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17:1\u201312.","journal-title":"Cell Mol Immunol"},{"key":"1663_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.coi.2018.03.015","volume":"51","author":"K Ben-Meir","year":"2018","unstructured":"Ben-Meir K, Twaik N, Baniyash M. Plasticity and biological diversity of myeloid derived suppressor cells. Curr Opin Immunol. 2018;51:154\u201361.","journal-title":"Curr Opin Immunol"},{"key":"1663_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208\u201320.","journal-title":"Trends Immunol"},{"key":"1663_CR13","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41375-021-01249-7","volume":"35","author":"G Ferrer","year":"2021","unstructured":"Ferrer G, Jung B, Chiu PY, Aslam R, Palacios F, Mazzarello AN, et al. Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia. 2021;35:3163\u201375.","journal-title":"Leukemia"},{"key":"1663_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","volume":"19","author":"F Veglia","year":"2018","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19:108\u201319.","journal-title":"Nat Immunol"},{"key":"1663_CR15","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/2326-6066.CIR-19-0008","volume":"7","author":"A Holtzhausen","year":"2019","unstructured":"Holtzhausen A, Harris W, Ubil E, Hunter DM, Zhao J, Zhang Y, et al. TAM family receptor kinase inhibition reverses MDSC-mediated suppression and augments anti-PD-1 therapy in melanoma. Cancer Immunol Res. 2019;7:1672\u201386.","journal-title":"Cancer Immunol Res"},{"key":"1663_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","volume":"44","author":"V Kumar","year":"2016","unstructured":"Kumar V, Cheng P, Condamine T, Mony S, Languino LR, McCaffrey JC, et al. CD45 phosphatase inhibits STAT3 transcription factor activity in myeloid cells and promotes tumor-associated macrophage differentiation. Immunity. 2016;44:303\u201315.","journal-title":"Immunity"},{"key":"1663_CR17","doi-asserted-by":"crossref","unstructured":"Bitsch R, Kurzay A, \u00d6zbay Kurt F, De La Torre C, Lasser S, Lepper A, et al. STAT3 inhibitor napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. J Immunother Cancer. 2022;10:e004384.","DOI":"10.1136\/jitc-2021-004384"},{"key":"1663_CR18","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1096\/fasebj.13.1.181","volume":"13","author":"Y Zhai","year":"1999","unstructured":"Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, et al. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J. 1999;13:181\u20139.","journal-title":"FASEB J"},{"key":"1663_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S1074-7613(02)00283-2","volume":"16","author":"TS Migone","year":"2002","unstructured":"Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, et al. TL1A is a TNF-like ligand for DR3 and TR6\/DcR3 and functions as a T cell costimulator. Immunity. 2002;16:479\u201392.","journal-title":"Immunity"},{"key":"1663_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.891328","volume":"13","author":"WD Xu","year":"2022","unstructured":"Xu WD, Li R, Huang AF. Role of TL1A in inflammatory autoimmune diseases: a comprehensive review. Front Immunol. 2022;13:891328.","journal-title":"Front Immunol"},{"key":"1663_CR21","doi-asserted-by":"publisher","first-page":"13451","DOI":"10.1073\/pnas.1404178111","volume":"111","author":"M Hedl","year":"2014","unstructured":"Hedl M, Abraham C. A TNFSF15 disease-risk polymorphism increases pattern-recognition receptor-induced signaling through caspase-8-induced IL-1. Proc Natl Acad Sci USA. 2014;111:13451\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1663_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.ajpath.2021.12.010","volume":"192","author":"RS Al-Lamki","year":"2022","unstructured":"Al-Lamki RS, Wang J, Pober JS, Bradley JR. Co-expression and functional interactions of death receptor 3 and E-selectin in clear cell renal cell carcinoma. Am J Pathol. 2022;192:722\u201336.","journal-title":"Am J Pathol"},{"key":"1663_CR23","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1038\/s41388-020-1322-4","volume":"39","author":"M Jiang","year":"2020","unstructured":"Jiang M, Zhang W, Zhang R, Liu P, Ye Y, Yu W, et al. Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene. 2020;39:4681\u201394.","journal-title":"Oncogene"},{"key":"1663_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112360","volume":"137","author":"C Ma","year":"2024","unstructured":"Ma C, Huang J, Zheng Y, Na Y, Wei J, Shan J, et al. Anti-TL1A monoclonal antibody modulates the dysregulation of Th1\/Th17 cells and attenuates granuloma formation in sarcoidosis by inhibiting the PI3K\/AKT signaling pathway. Int Immunopharmacol. 2024;137:112360.","journal-title":"Int Immunopharmacol"},{"key":"1663_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2032918","volume":"11","author":"CC Zhao","year":"2022","unstructured":"Zhao CC, Han QJ, Ying HY, Gu XX, Yang N, Li LY, et al. TNFSF15 facilitates differentiation and polarization of macrophages toward M1 phenotype to inhibit tumor growth. Oncoimmunology. 2022;11:2032918.","journal-title":"Oncoimmunology"},{"key":"1663_CR26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-0-387-89520-8_15","volume":"647","author":"G Sethi","year":"2009","unstructured":"Sethi G, Sung B, Aggarwal BB. Therapeutic potential of VEGI\/TL1A in autoimmunity and cancer. Adv Exp Med Biol. 2009;647:207\u201315.","journal-title":"Adv Exp Med Biol"},{"key":"1663_CR27","doi-asserted-by":"publisher","first-page":"5352","DOI":"10.1182\/blood-2008-08-173773","volume":"113","author":"F Tian","year":"2009","unstructured":"Tian F, Liang PH, Li LY. Inhibition of endothelial progenitor cell differentiation by VEGI. Blood. 2009;113:5352\u201360.","journal-title":"Blood"},{"key":"1663_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10456-010-9195-8","volume":"14","author":"PH Liang","year":"2011","unstructured":"Liang PH, Tian F, Lu Y, Duan B, Stolz DB, Li LY. Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis. 2011;14:61\u20138.","journal-title":"Angiogenesis"},{"key":"1663_CR29","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.4049\/jimmunol.179.6.3742","volume":"179","author":"F Tian","year":"2007","unstructured":"Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL, Li LY. The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. J Immunol. 2007;179:3742\u201351.","journal-title":"J Immunol"},{"key":"1663_CR30","doi-asserted-by":"publisher","first-page":"13863","DOI":"10.1073\/pnas.1304529110","volume":"110","author":"JW Qi","year":"2013","unstructured":"Qi JW, Qin TT, Xu LX, Zhang K, Yang GL, Li J, et al. TNFSF15 inhibits vasculogenesis by regulating relative levels of membrane-bound and soluble isoforms of VEGF receptor 1. Proc Natl Acad Sci USA. 2013;110:13863\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1663_CR31","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-05-0384","volume":"11","author":"W Hou","year":"2005","unstructured":"Hou W, Medynski D, Wu S, Lin X, Li LY. VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res. 2005;11:5595\u2013602.","journal-title":"Clin Cancer Res"},{"key":"1663_CR32","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.4049\/jimmunol.161.10.5313","volume":"161","author":"V Bronte","year":"1998","unstructured":"Bronte V, Wang M, Overwijk WW, Surman DR, Pericle F, Rosenberg SA, et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+\/Gr-1+ cells. J Immunol. 1998;161:5313\u201320.","journal-title":"J Immunol"},{"key":"1663_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"1663_CR34","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","volume":"68","author":"P Serafini","year":"2008","unstructured":"Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68:5439\u201349.","journal-title":"Cancer Res"},{"key":"1663_CR35","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2013.02.007","volume":"38","author":"M Sade-Feldman","year":"2013","unstructured":"Sade-Feldman M, Kanterman J, Ish-Shalom E, Elnekave M, Horwitz E, Baniyash M. Tumor necrosis factor-\u03b1 blocks differentiation and enhances suppressive activity of immature myeloid cells during chronic inflammation. Immunity. 2013;38:541\u201354.","journal-title":"Immunity"},{"key":"1663_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","volume":"222","author":"PC Rodr\u00edguez","year":"2008","unstructured":"Rodr\u00edguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008;222:180\u201391.","journal-title":"Immunol Rev"},{"key":"1663_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/sji.70001","volume":"101","author":"M Awad","year":"2025","unstructured":"Awad M, Sen\u2019kova A, Zenkova M, Markov O. The impact of cytokines and tumour-conditioned medium on the properties of murine in vitro generated myeloid-derived suppressor cells. Scand J Immunol. 2025;101:e70001.","journal-title":"Scand J Immunol"},{"key":"1663_CR38","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.4049\/jimmunol.177.10.7303","volume":"177","author":"FO Martinez","year":"2006","unstructured":"Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303\u201311.","journal-title":"J Immunol"},{"key":"1663_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.molimm.2019.11.014","volume":"117","author":"BH Li","year":"2020","unstructured":"Li BH, Garstka MA, Li ZF. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol Immunol. 2020;117:201\u201315.","journal-title":"Mol Immunol"},{"key":"1663_CR40","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","volume":"39","author":"V Bronte","year":"2013","unstructured":"Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013;39:806\u201318.","journal-title":"Immunity"},{"key":"1663_CR41","doi-asserted-by":"crossref","unstructured":"Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, et al. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021;13:eabb0130.","DOI":"10.1126\/scitranslmed.abb0130"},{"key":"1663_CR42","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","volume":"184","author":"S Kaczanowska","year":"2021","unstructured":"Kaczanowska S, Beury DW, Gopalan V, Tycko AK, Qin H, Clements ME, et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell. 2021;184:2033\u201352.e21.","journal-title":"Cell"},{"key":"1663_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","volume":"27","author":"J Yu","year":"2021","unstructured":"Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27:152\u201364.","journal-title":"Nat Med"},{"key":"1663_CR44","doi-asserted-by":"crossref","unstructured":"Liu M, Wu C, Luo S, Hua Q, Chen HT, Weng Y, et al. PERK reprograms hematopoietic progenitor cells to direct tumor-promoting myelopoiesis in the spleen. J Exp Med. 2022;219:e20211498.","DOI":"10.1084\/jem.20211498"},{"key":"1663_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","volume":"70","author":"PY Pan","year":"2010","unstructured":"Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 2010;70:99\u2013108.","journal-title":"Cancer Res"},{"key":"1663_CR46","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1182\/blood-2012-05-427799","volume":"120","author":"J Huang","year":"2012","unstructured":"Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 2012;120:3030\u20138.","journal-title":"Blood"},{"key":"1663_CR47","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1182\/blood-2010-11-321752","volume":"117","author":"P Sinha","year":"2011","unstructured":"Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA, Ostrand-Rosenberg S. Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 2011;117:5381\u201390.","journal-title":"Blood"},{"key":"1663_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8661423","volume":"2022","author":"Z He","year":"2022","unstructured":"He Z, Wang S, Wu J, Xie Y, Li B. Lower expression of TWEAK is associated with poor survival and dysregulate TIICs in lung adenocarcinoma. Dis markers. 2022;2022:8661423.","journal-title":"Dis markers"},{"key":"1663_CR49","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.7150\/thno.33275","volume":"9","author":"SHL Hoffmann","year":"2019","unstructured":"Hoffmann SHL, Reck DI, Maurer A, Fehrenbacher B, Sceneay JE, Poxleitner M, et al. Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer. Theranostics. 2019;9:5869\u201385.","journal-title":"Theranostics"},{"key":"1663_CR50","first-page":"55","volume":"1846","author":"P Trikha","year":"2014","unstructured":"Trikha P, Carson WE 3rd. Signaling pathways involved in MDSC regulation. Biochim Biophys Acta. 2014;1846:55\u201365.","journal-title":"Biochim Biophys Acta"},{"key":"1663_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3\u20138.","journal-title":"Cancer Immunol Res"},{"key":"1663_CR52","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/jleuko\/qiae013","volume":"115","author":"K Mahanti","year":"2024","unstructured":"Mahanti K, Saha J, Sarkar D, Pramanik A, Roy Chattopadhyay N, Bhattacharyya S. Alteration of functionality and differentiation directed by changing gene expression patterns in myeloid-derived suppressor cells (MDSCs) in tumor microenvironment and bone marrow through early to terminal phase of tumor progression. J Leukoc Biol. 2024;115:958\u201384.","journal-title":"J Leukoc Biol"},{"key":"1663_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1157537","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Du J, Shen X. Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond. Front Immunol. 2023;14:1157537.","journal-title":"Front Immunol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01663-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T15:04:46Z","timestamp":1768575886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01663-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1663"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01663-y","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}